However, CCL5 levels in tumor tissue were higher in breast cancer patients with ER-negative (P = 0.034) or PR-negative (P = 0.009) tumors, a higher nuclear grade (P = 0.013) and a later clinical stage (P < 0.001). This evidence concerns the gene ESR1 and breast cancer.